Telix touts studies at EANM 2023

2018 12 11 00 02 7009 Atom Nuclear Lab 400

Telix Pharmaceuticals is highlighting studies set to be presented at the European Association of Nuclear Medicine meeting to be held September 9-13 in Vienna.

Specifically, new data will be presented in on oral session on September 10 from the company's phase III trial evaluating the sensitivity and specificity of zirconium 89 (Zr-89) TLX250 PET/CT to detect clear cell renal cell cancer (ccRCC) in adult patients with indeterminate renal masses, Telix said.

In addition, the following Telix initiatives will also be presented:

  • A phase III study of the company's TLX591 investigational prostate cancer therapy
  • A session covering AI segmentation and primary characterization of prostate cancer lesions using models trained on gallium 68 (Ga-68) PSMA-11 PET/CT image datasets
  • The Nobody Left Behind (NOBLE) Registry of Telix's SPECT-based prostate cancer imaging agent TLX599-CDx
  • A preclinical evaluation of carbonic anhydrase IX (CAIX)-targeted lutetium-177 radionuclide therapy in combination with immune checkpoint inhibition
Page 1 of 458
Next Page